Evidence map›Paper›PMID 41419801›Full record

ArticleBMC microbiology2025

Current drug susceptibility testing in the Löwenstein-Jensen medium leads to underestimating of prothionamide resistance in multi-drug resistant Mycobacterium tuberculosis.

Xinchang Chen, Yuanyuan Chen, Guiqing He, Shiyong Wang, Siran Lin, Jiazhen Chen, Wenhong Zhang

Abstract read
In one paragraph

Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xinchang ChenDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Yuanyuan ChenTuberculosis diagnosis and treatment center, Hangzhou Red Cross Hospital, Hangzhou, China.
Guiqing HeLaboratory of Infectious Diseases, Wenzhou Central Hospital, The Dingli Clinical College of Wenzhou Medical University, Wenzhou, China.
Shiyong WangDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Siran LinDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Jiazhen ChenDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. jiazhen_chen@163.com.
Wenhong ZhangDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.

Funding

Basic Public Welfare Research Program of Zhejiang Province LGF20H010003National Natural Science Foundation of China 82202568Shangda Translational Medicine Foundation of Wenzhou Research Institute of Shanghai University SDTMF2022EP02Shanghai Sailing Program 22YF1445700
6 · The paper itself

Abstract

purposeThis study aimed to resolve inconsistencies in prothionamide (PTO) drug susceptibility testing (DST) results between solid and liquid media by validating the appropriate critical concentrations for PTO DST in solid media. It also aimed to assess the correlation between phenotypic resistance and genetic mutations in ethA and the inhA promoter.

methodsA total of 100 multidrug-resistant tuberculosis (MDR-TB) isolates were tested for PTO susceptibility using the MGIT 960 system, Löwenstein-Jensen (L-J) medium, and Middlebrook 7H10 medium with varying PTO concentrations. Genotypic resistance was determined by PCR and sequencing of ethA and the inhA promoter.

resultsWhen MGIT 960 was used as the reference, 20 mg/L for L-J and 10 mg/L for 7H10 achieved the highest agreement (kappa = 0.865 and 0.827, respectively). Using Sanger sequencing as the reference, the highest kappa (0.594) was observed for MGIT 960 when defining resistance as inhA c-15t and/or loss-of-function mutations in ethA. At 20 mg/L, L-J medium provided a balanced sensitivity (71.4%) and specificity (84.6%), whereas 40 mg/L increased specificity but markedly reduced sensitivity. Six isolates showed suboptimal growth on 7H10, suggesting it may not support robust culture of MDR strains. Wild-type inhA and ethA profiles demonstrated high negative predictive value (NPV 90.2–100.0%), reliably excluding resistance.

conclusionsA critical concentration of 40 mg/L for PTO in L-J medium may underestimate resistance. A lower concentration of 20 mg/L offers improved detection but requires genotypic confirmation owing to lower PPV. The 7H10 medium may not be optimal for MDR-TB DST due to limited growth support. Integrating phenotypic and molecular methods is recommended for accurate resistance detection.

Indexed as

Antitubercular AgentsCulture MediaDrug Resistance, Multiple, BacterialMycobacterium tuberculosisProthionamideTuberculosis, Multidrug-ResistantBacterial ProteinsGenotypeHumansMicrobial Sensitivity TestsMutationOxidoreductasesPromoter Regions, GeneticAntitubercular AgentsBacterial ProteinsCulture MediaInhA protein, MycobacteriumOxidoreductasesProthionamideDrug-resistant tuberculosisDrug-susceptibility testEthA geneInhA geneProthionamideResistance-related gene

Identifiers

PMID41419801
PMCPMC12874661

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.